细胞周期蛋白依赖性激酶抑制剂在结直肠癌治疗中的前景
摘要
抑制肿瘤细胞增殖、控制疾病进展和提高存活率方面显示出显著效果而备受青睐，已成为目前抗癌药物研发的热点。到目前
为止，已有 4 种高度选择性的 CDK4/6 抑制剂获批上市，分别是治疗乳腺癌的 Palbociclib、Ribociclib 和 Abemaciclib 以及治
疗小细胞肺癌的 Trilaciclib。大量研究发现，包括 CDK4/6 在内的多种 CDK 在结直肠癌（CRC）中异常表达，并可能参与 CRC
的发生、发展。且多项研究表明，细胞周期蛋白依赖性激酶抑制剂（CDKI）可增强化疗、靶向和免疫诱导的抗 CRC 作用，
从而提高了 CRC 的治愈率，可见 CDKI 与其他治疗的联合似乎为治愈 CRC 带来新的曙光。这篇综述中，我们将关注各种 CDK
的功能及其抑制剂（尤其是 CDK4/6 抑制剂）在 CRC 治疗中的潜在作用，旨在探讨 CDK4/6 抑制剂在 CRC 治疗中的应用前
景及优化手段。
关键词
全文:
PDF参考
[1] Whittaker SR, Mallinger A, et al. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol
Ther. 2017 May;173:83-105. [2] Somarelli JA, Roghani RS, et al. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9
Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Mol Cancer Ther. 2020 Dec;19(12):2516-2527. [3] 刘子齐,左涛,徐锋,等. CDK4/6 信号通路靶向治疗剂
在癌症治疗中的研究进展. 生物工程学报, 2021, 37(7): 2232-2239. [4] Thoma OM, Neurath MF, Waldner MJ. Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment. Front Pharmacol. 2021 Dec 21;12:757120. [5] Liu ＭＨ，Liu ＨＹ，Chen J．Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991）and its future
application in cancer treatmen（t Review）[J]．Oncol Rep，2018，
39（３）：901－911
[6] 刘艳华,王明权,朱伟英,等. CDK4/6 抑制剂在消化道
肿 瘤 中 的 临 床 研 究 进 展 [J]. 中 国 现 代 应 用 药
学,2021,38(18):2333-2336. [7] Wang D, et al. CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients. Int J Gen Med. 2022 Feb 27;15:2233-2245.。
[8] Sung WW, et al. High nuclear/cytoplasmic ratio of
CDK1 expression predicts poor prognosis in colorectal cancer patients. BMC Cancer. 2014 Dec 15;14:951. [9] 张朝霞,梁建芳,郑绘霞,等. BAG-1、CDK4 蛋白在结
直肠癌中的表达及意义[J]. 中国医药导报,2010,7(7):16-18. [10] 潘长海,彭洪云. 周期素 A 和 CDK2 在结直肠癌中
的表达及其临床意义[J]. 江苏医药,2011,37(13):1568-1570,封
3. [11] Huang, P. H., et al. (2016). Cdk5 Directly Targets Nuclear p21CIP1 and Promotes Cancer Cell Growth. Cancer Res. 76, 6888–6900. [12] Ruiz de Porras V, Bystrup S, et al. Tumor Expression
of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated
Metastatic Colorectal Cancer Patients. Cancers (Basel). 2019
Oct 11;11(10):1540. [13] 孔祥璀. CDK-8 和 MMP-7 在结直肠癌组织中的表
达及相关性分析[D]. 广州医科大学,2014. [14] Wang, J., Liu, J., et al (2019). Cyclin-dependent
Kinase 9 Expression and its Association with CD8+ T Cell
Infiltration in Microsatellite-Stable Colorectal Cancer. Oncol. Lett. 18, 6046–6056. [15] Klein, M.E, et al.（2018）.CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell 34, 9–20. [16] Costa-Cabral S, Brough R, et al. Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS
One. 2017 Apr 20;12(4):e0176578. [17] Ziemke EK, Dosch JS, et al. Sensitivity of
KRAS-Mutant Colorectal Cancers to Combination Therapy That
Cotargets MEK and CDK4/6. Clin Cancer Res. 2016 Jan
15;22(2):405-14. [18] Witalisz-Siepracka A，et al. NK cell-specific CDK8
deletion enhances antitumor response［s J］. Cancer Immunol Res，
2018，6 （4）：458-466. [19] Pu Y, Yan D, et al. CDK Inhibition Reverses Acquired
5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. Dis Markers. 2022 Mar 11;2022:6907057. [20] Zhu, Y., Li, K., Zhang, J., et al. (2020). Inhibition of
CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer. Cancer Manag. Res. 12, 11271–11283. [21] Kumar A, Singh AK, et al. Regulation of thymidylate
synthase: an approach to overcome 5-FU resistance in colorectal cancer. Med Oncol. 2022 Oct 29;40(1):3. [22] Takagi K, Sowa Y, et al. CDK inhibitor enhances the
sensitivity to 5-fluorouracil in colorectal cancer cells. Int J
Oncol. 2008 May;32(5):1105-10. [23] Tong J, Tan X, Song X, et al. CDK4/6 inhibition
suppresses p73 phosphorylation and activates DR5 to potentiate
chemotherapy and immune checkpoint blockade. Cancer Res. 2022;82:1340–52. [24] 陈燕平,钱丹雯,高潺潺,等. 化疗联合热疗治疗大肠
癌肝转移疗效观察[J]. 南京医科大学学报（自然科学
版）,2015,35(1):96-98,101. [25] Dhillon S. Trilaciclib: First Approval. Drugs. 2021
May;81(7):867-874. [26] Du Q, et al. The application and prospect of CDK4/6
inhibitors in malignant solid tumors. J Hematol Oncol. 2020
May 1;13(1):41. [27] Chen SH, Gong X, et al. RAF inhibitor LY3009120
sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition
by abemaciclib via superior inhibition of phospho-RB and
suppression of cyclin D1. Oncogene. 2018;37:821–32. [28] Pek M, Yatim S, et al. Oncogenic KRAS-associated
gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Oncogene. 2017;36:4975–86. [29] Zhang P, Kawakami H, et al. Targeting CDK1 and
MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant
Human Colorectal Cancer. Mol Cancer Res. 2018
Mar;16(3):378-389. [30] Hermanowicz JM, Pawlak K, et al. MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer. Cancers (Basel). 2021 Jun 26;13(13):3203. [31] Lee HJ, Kim KJ, et al. PI3K p110 α Blockade
Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells. Cancers (Basel). 2020 Sep
3;12(9):2500. [32] Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel). 2017
May 17;9(5):52. [33] Wang Y, Liao H, et al. Conditionally reprogrammed
colorectal cancer cells combined with mouse avatars identify
synergy between EGFR and MEK or CDK4/6 inhibitors. Am J
Cancer Res. 2020 Jan 1;10(1):249-262. [34] Lelliott EJ, Kong IY, et al. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell
Memory. Cancer Discov. 2021 Oct;11(10):2582-2601. [35] Goel S, DeCristo MJ, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 2017;548:471–5
[36] Teh JLF, Aplin AE. Arrested developments: CDK4/6
inhibitor resistance and alterations in the tumor immune microenvironment [J]. Clin Cancer Res, 2019, 25(3): 921- 927. [37] Deng J, Wang ES, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov 2018;8:216–33. [38] Wagner V, Gil J. Senescence as a therapeutically
relevant response to CDK4/6 inhibitors. Oncogene, 2020, 39(29): 5165-5176.
Refbacks
- 当前没有refback。
数据库合作单位
